Sign in

    Lin Hisao

    Research Analyst at Goldman Sachs

    No publicly available information could be found confirming the existence of Lin Hisao as an analyst at Goldman Sachs. There are no LinkedIn profiles, professional bios, or performance records available from reputable industry databases, financial ranking platforms, or Goldman Sachs directories. As a result, no detailed professional profile, career history, company coverage, performance metrics, or credentials can be provided for this individual.

    Lin Hisao's questions to Zai Lab (ZLAB) leadership

    Lin Hisao's questions to Zai Lab (ZLAB) leadership • Q1 2024

    Question

    Lin Hisao of Goldman Sachs asked about the filing plans for adagrasib following recent trial data and the expected timeline for an MAA submission for Optune in second-line NSCLC in China.

    Answer

    Dr. Rafael Amado, President and Head of Global Oncology R&D, explained that for adagrasib, they are awaiting further data evaluation by partner BMS before finalizing plans. For Optune, he confirmed they expect to submit the MAA in China this year based on the LUNAR study results, without necessarily waiting for FDA approval.

    Ask Fintool Equity Research AI